Evidence map›Paper›PMID 37995354›Full record

ArticleThe Journal of antimicrobial chemotherapy2023

COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.

Sabine Bou-Antoun, Sakib Rokadiya, Diane Ashiru-Oredope, Alicia Demirjian, Emma Sherwood, Nicholas Ellaby, Sarah Gerver, Carlota Grossi, Katie Harman, Hassan Hartman and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Lessons identified for a future pandemic.The Journal of antimicrobial chemotherapy · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Sabine Bou-AntounHealthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.ORCID 0000-0002-5640-1490
Sakib RokadiyaGenomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK.
Diane Ashiru-OredopeHealthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.ORCID 0000-0001-9579-2028
Alicia DemirjianHealthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.
Emma SherwoodClinical and Emerging Infections (CEI), United Kingdom Health Security Agency (UKHSA), London, UK.
Nicholas EllabyGenomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK.
Sarah GerverHealthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.
Carlota GrossiCOVID-19 Rapid Evidence Service Public Health Advice, Guidance and Expertise (PHAGE), UK Health Security Agency, London NW9 5EQ, UK.
Katie HarmanCOVID-19 Vaccines and Applied Epidemiology Division, UK Health Security Agency, London NW9 5EQ, UK.
Hassan HartmanGenomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK.
Alessandra LochenTuberculosis (TB), Acute Respiratory, Zoonoses, Emerging and Travel infections Division, UK Health Security Agency, London NW9 5EQ, UK.ORCID 0000-0002-8068-1293
Manon Ragonnet-CroninGenomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK.
Hanna SquireHealthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.
J Mark SuttonResearch and Evaluation, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.
Simon ThelwallCOVID-19 Vaccines and Applied Epidemiology Division, UK Health Security Agency, London NW9 5EQ, UK.
Julia TreeResearch and Evaluation, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.
Mohammad W BaharDivision of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
David I StuartDivision of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
Colin S BrownHealthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.
Meera ChandGenomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK.
Susan HopkinsHealthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.

Funding

Health Protection Research UnitNational Institute for Health ResearchUKRI MRC MR/N00065X/1
6 · The paper itself

Abstract

The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics.

Indexed as

COVID-19Anti-Bacterial AgentsAntiviral AgentsDrug Resistance, BacterialEnglandHumansPandemicsSARS-CoV-2Anti-Bacterial AgentsAntiviral Agents

Identifiers

PMID37995354
PMCPMC10666993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.